SIGA Technologies

SIGA Technologies Overview

Company Headquarters: New York, US

Founded: 1995

Workforce: ~50

Company Working: SIGA Technologies (SIGA) is a pharmaceutical business at the commercialization stage that develops and offers antiviral treatments for smallpox, monkeypox, cowpox, and vaccinia complications. The company has an established research and development collaboration with US federal entities. It provides countermeasures to the Strategic National Stockpile (SNS) and the Department of Defense (DoD). TPOXX ("oral TPOXX," also known as "tecovirimat" in certain overseas markets) is the Company's lead product, which it distributes to the US government and international governments (including government-affiliated entities). In addition, the Company sells TPOXX intravenous formulation ("IV TPOXX") to the US Government

Strategy

SIGA's business strategy includes ongoing international sales of TPOXX to foreign governments. Foreign governments, as well as state and local governments, non-governmental organizations focused on global health such as the World Health Organization, health care institutions such as hospitals (domestic and foreign), and certain large business organizations interested in protecting their employees from global threats and first responders in the event of an emergency are among the non-US Government customers

Company Snapshot

$115.5M

Revenue

50

Employees

1995

Founded

New York, US

Headquarters

SWOT Analysis

Strengths

High focus on innovation
Continually invests in research and development
Increasingly flexible and adaptive to change

Weaknesses

Restricted patent protection
Stagnant groups of target consumers
No expansion in emerging economies

Opportunities

Development of strategic alliances and partnerships
Focus on building a high service culture

Threats

High competition
Government regulations and policies
High price volatility and fluctuations in the acquisition of raw materials

Key Developments

Date	Approach	Development
September 2022	Investment	SIGA Technologies announced new contract awarded by U.S. Department of Defense for the procurement of up to 10.7 million of oral TPOXX.
July 2022	Product Approval	SIGA Technologies announced that the UK has approved SIGA's oral tecovirimat (also known as oral TPOXX in the United States) for the treatment of smallpox, monkeypox, cowpox, and vaccinia problems following smallpox immunization in adults and children weighing at least 13kg.
May 2022	Product Approval	SIGA Technologies announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for the treatment of smallpox. The IV formulation is an important option for those who are unable to swallow the oral capsules of TPOXX.
July 2021	Collaboration	SIGA Technologies established a collaboration with Oxford University in the United Kingdom (UK) to supply TPOXX (tecovirimat) under an expanded access policy to treat monkeypox patients in the Central African Republic (CAR). The protocol and study in CAR will be sponsored by Oxford University, and SIGA will supply up to 500 free courses of TPOXX (tecovirimat).
June 2019	Agreement	SIGA Technologies has announced an international promotion agreement with Meridian Medical Technologies, Inc. (US) ("Meridian", a Pfizer Company). Meridian will promote the sale of oral TPOXX for the treatment of smallpox in all markets excluding the United States and South Korea under the terms of the agreement. SIGA will retain ownership of all rights in the US market.

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.